Are Once-Weekly GLP-1 Medications More Effective Than DPP-4 Inhibitors for Blood Sugar and Weight in Real-World Diabetes Care?
Once-weekly GLP-1 receptor agonists, especially semaglutide, produced significantly greater HbA1c reductions and weight loss than DPP-4 inhibitors in a large real-world type 2 diabetes population.
Quick Facts
What This Study Found
Semaglutide users achieved 1.7% HbA1c reduction and 4.1 kg weight loss vs 0.9% and 1.3 kg for DPP-4 inhibitor users over 12 months, with GLP-1 patients at least twice as likely to hit composite endpoints.
Key Numbers
Compared two treatment cohorts. Primary outcomes: HbA1c and weight changes.
How They Did This
Observational cohort study using linked IQVIA PharMetrics Plus and Ambulatory EMR databases (January 2017–April 2022), with inverse probability of treatment weighting to adjust for baseline differences between groups.
Why This Research Matters
While clinical trials have established GLP-1 superiority, this real-world evidence confirms those benefits hold up in everyday clinical practice, supporting guideline recommendations to prioritize GLP-1 therapies for patients needing both glycemic control and weight management.
The Bigger Picture
This study adds to the growing body of real-world evidence supporting current guidelines that recommend GLP-1 receptor agonists as preferred second-line therapies for type 2 diabetes, especially when weight management is a priority alongside glycemic control.
What This Study Doesn't Tell Us
Observational design limits causal inference despite statistical adjustments; US-focused data may not generalize globally; relatively small semaglutide subgroup (N=354); limited to 12-month follow-up; potential for residual confounding.
Questions This Raises
- ?Do the real-world advantages of GLP-1 RAs over DPP-4 inhibitors persist beyond 12 months?
- ?How do newer agents like tirzepatide compare to semaglutide in real-world head-to-head analyses?
- ?What patient characteristics predict the greatest benefit from switching from DPP-4i to GLP-1 RA therapy?
Trust & Context
- Key Stat:
- −4.1 kg vs −1.3 kg weight loss with semaglutide vs DPP-4 inhibitors over 12 months
- Evidence Grade:
- Moderate evidence from a large real-world observational study using statistical adjustments, but limited by non-randomized design and potential residual confounding.
- Study Age:
- Published in 2024 using data through April 2022, providing recent real-world evidence for once-weekly GLP-1 medications.
- Original Title:
- Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
- Published In:
- Clinical drug investigation, 44(4), 271-284 (2024)
- Authors:
- Tan, Xi(3), Divino, Victoria(3), Amamoo, James(2), Xie, Lin, Coyle, Katharine B, Gamble, Cory L, Guevarra, Mico, Paprocki, Yurek, King, Aaron A
- Database ID:
- RPEP-09365
Evidence Hierarchy
Frequently Asked Questions
How much better are weekly GLP-1 shots than DPP-4 pills for type 2 diabetes?
In this real-world study, semaglutide users saw nearly double the HbA1c reduction (1.7% vs 0.9%) and triple the weight loss (4.1 kg vs 1.3 kg) compared to DPP-4 inhibitor users over one year.
Do GLP-1 medications work as well in real life as they do in clinical trials?
Yes — this study confirms that real-world results align with clinical trial findings, with GLP-1 patients being at least twice as likely to achieve both blood sugar and weight targets compared to DPP-4 inhibitor patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09365APA
Tan, Xi; Divino, Victoria; Amamoo, James; Xie, Lin; Coyle, Katharine B; Gamble, Cory L; Guevarra, Mico; Paprocki, Yurek; King, Aaron A. (2024). Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).. Clinical drug investigation, 44(4), 271-284. https://doi.org/10.1007/s40261-024-01354-2
MLA
Tan, Xi, et al. "Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).." Clinical drug investigation, 2024. https://doi.org/10.1007/s40261-024-01354-2
RethinkPeptides
RethinkPeptides Research Database. "Real-World Effectiveness of Once-Weekly Glucagon-Like Peptid..." RPEP-09365. Retrieved from https://rethinkpeptides.com/research/tan-2024-realworld-effectiveness-of-onceweekly
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.